Oppenheimer Initiates Coverage on Whitehawk Therapeutics (NASDAQ:WHWK)

Research analysts at Oppenheimer assumed coverage on shares of Whitehawk Therapeutics (NASDAQ:WHWK) in a report issued on Thursday, MarketBeat reports. The firm set an “outperform” rating and a $6.00 price target on the stock. Oppenheimer’s target price points to a potential upside of 106.90% from the stock’s previous close.

A number of other analysts have also issued reports on the company. Jones Trading started coverage on Whitehawk Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target on the stock. Wall Street Zen lowered shares of Whitehawk Therapeutics to a “strong sell” rating in a research report on Saturday, November 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $6.50.

Whitehawk Therapeutics Stock Performance

NASDAQ:WHWK remained flat at $2.90 during trading hours on Thursday. 46,809 shares of the company’s stock were exchanged, compared to its average volume of 115,487. The stock has a fifty day moving average of $2.59 and a 200-day moving average of $2.20. The firm has a market cap of $136.68 million, a price-to-earnings ratio of 20.71 and a beta of 0.59. Whitehawk Therapeutics has a 52 week low of $1.39 and a 52 week high of $3.77.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.25.

Institutional Trading of Whitehawk Therapeutics

Several institutional investors have recently made changes to their positions in WHWK. ABG Innovation Capital Partners III GP Ltd acquired a new position in Whitehawk Therapeutics in the third quarter valued at approximately $51,000. Dimensional Fund Advisors LP purchased a new position in shares of Whitehawk Therapeutics during the 3rd quarter worth $84,000. Squarepoint Ops LLC acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth about $159,000. Citadel Advisors LLC acquired a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth about $266,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Whitehawk Therapeutics in the 3rd quarter valued at about $409,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.